These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6035 related articles for article (PubMed ID: 3102397)

  • 1. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
    Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
    Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
    Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
    Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
    O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
    Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
    Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
    Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
    Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
    J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
    Croghan MK; Booth A; Meyskens FL
    J Biol Response Mod; 1988 Aug; 7(4):409-15. PubMed ID: 3139843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.
    Ajani JA; Ota DM; Grossie VB; Abbruzzese JL; Faintuch JS; Patt YZ; Jackson DE; Levin B; Nishioka K
    Cancer Chemother Pharmacol; 1990; 26(3):223-6. PubMed ID: 2113439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
    Horn Y; Schechter PJ; Marton LJ
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1103-7. PubMed ID: 3115786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
    Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
    Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible ototoxicity associated with difluoromethylornithine.
    Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
    Griffin CA; Slavik M; Chien SC; Hermann J; Thompson G; Blanc O; Luk GD; Baylin SB; Abeloff MD
    Invest New Drugs; 1987; 5(2):177-86. PubMed ID: 3115911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difluoromethylornithine in cancer: new advances.
    Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
    Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
    Bailey HH; Kim K; Verma AK; Sielaff K; Larson PO; Snow S; Lenaghan T; Viner JL; Douglas J; Dreckschmidt NE; Hamielec M; Pomplun M; Sharata HH; Puchalsky D; Berg ER; Havighurst TC; Carbone PP
    Cancer Prev Res (Phila); 2010 Jan; 3(1):35-47. PubMed ID: 20051371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
    Abeloff MD; Slavik M; Luk GD; Griffin CA; Hermann J; Blanc O; Sjoerdsma A; Baylin SB
    J Clin Oncol; 1984 Feb; 2(2):124-30. PubMed ID: 6422008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.
    Prakash NJ; Sunkara PS; Sjoerdsma A
    Biochem Pharmacol; 1985 Jun; 34(11):1887-90. PubMed ID: 3924051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
    Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
    Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-related alpha-difluoromethylornithine ototoxicity.
    Croghan MK; Aickin MG; Meyskens FL
    Am J Clin Oncol; 1991 Aug; 14(4):331-5. PubMed ID: 1862765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
    Splinter TA; Romijn JC
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
    Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G
    J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 302.